February 2026
DMT
What February 2026's 12 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.
In February 2026, research on DMT and its analog 5-MeO-DMT showed promising but preliminary therapeutic effects for treatment-resistant depression, with one open-label study reporting rapid and sustained symptom reduction over 12 weeks. However, the evidence remains largely observational and limited by small sample sizes, lack of placebo controls, and unresolved questions about endogenous DMT's role in the brain. The overall confidence in these findings is low due to the scarcity of controlled trials and the preliminary nature of the available data.
Confidence in the evidence
Low- Only one clinical trial (article_id: 24992) was an open-label, uncontrolled study with no placebo comparator, limiting causal inference.
- Multiple reviews (article_ids: 24815, 24897, 24839) highlight that most evidence is observational or from small studies, with calls for larger randomized controlled trials.
- A systematic review (article_id: 24835) of psychedelics including DMT found mixed effects on cognitive functions and noted small sample sizes and difficulty with placebo blinding.
- Preclinical studies (article_ids: 24832, 24829) failed to detect endogenous DMT in rat brain, challenging the hypothesis of DMT as a natural neurotransmitter.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression 2026 | open-label uncontrolled trial | Supports | Intranasal BPL-003 (5-MeO-DMT) was safe and associated with rapid and sustained reduction in MADRS scores over 12 weeks in treatment-resistant depression. | |
| Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind 2026 | review | Supports | Reviews current evidence on DMT and 5-MeO-DMT for mental disorders, highlighting therapeutic potential through 5-HT2A and 5-HT1A receptor agonism and neuroplasticity, but notes limited clinical trials. | |
| We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐ N , N ‐Dimethyltryptamine 2026 | review | Unclear | Reviews chemical syntheses of bufotenin and 5-MeO-DMT, noting increased preclinical and clinical research interest but not providing clinical efficacy data. | |
| Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies 2026 | review | Supports | Summarizes preclinical and clinical evidence on ayahuasca/DMT for multiple mental disorders, showing enhanced neuroplasticity and reduced DMN activity, but evidence is mainly observational and requires randomized trials. | |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine 2026 | review | Supports | Describes 5-MeO-DMT as a promising ultra-short-acting psychedelic for treatment-resistant depression, warranting larger RCTs. | |
| Consciousness Field EFT (43 Hz): EEG Evidence from DMT Breakthrough & Meditation (N=35 Subjects) 2026 | observational | 35 | Supports | EEG data showed selective gamma-band power enhancement near 43 Hz during peak conscious states (DMT/5-MeO-DMT breakthrough) compared to baselines, with non-random dynamics. |
| Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature 2026 | systematic review | Mixed | Psychedelics enhanced emotional empathy but had mixed effects on memory, reaction time, attention, and cognitive flexibility; many studies had small samples and placebo blinding challenges. | |
| Toxicometabolomics Characterization of Two N1-Sulfonated Dimethyltryptamine Derivatives in Zebrafish Larvae and Human Liver S9 Fractions Using Liquid Chromatography-High-Resolution Mass Spectrometry. 2026 | preclinical | Unclear | Characterized metabolism of N1-sulfonated DMT derivatives, identifying phase I/II biotransformations and downregulation of L-threonine, but no clinical outcomes. | |
| The Axis Mundi Hypothesis: Endogenous N,N-Dimethyltryptamine as a Neurobiological Bridge Between Conscious and Subconscious Processing - An Integrative Theoretical Framework 2026 | theoretical | Unclear | Proposes the Axis Mundi hypothesis that endogenous DMT serves dual functions: neuroprotection via sigma-1 receptor agonism and modulation of conscious-subconscious boundary via 5-HT2A receptors. | |
| N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain. 2026 | preclinical | Opposes | Endogenous DMT was undetectable in rat brain despite MAO inhibition, and exogenous DMT was not retained in serotonin terminals, challenging the hypothesis of DMT as a co-transmitter with serotonin. | |
| N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain 2026 | preclinical | Opposes | Same findings as article_id 24832: endogenous DMT below detection limits, and no evidence of DMT formation or retention in serotonin terminals. | |
| Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders 2026 | theoretical/patent | Supports | Describes a vaporizable formulation of 5-MeO-DMT and THCV as a potential treatment for TRD and anxiety, aiming to reduce panic responses while preserving neuroplastic benefits. |
Intranasal BPL-003 (5-MeO-DMT) was safe and associated with rapid and sustained reduction in MADRS scores over 12 weeks in treatment-resistant depression.
open-label uncontrolled trial
Reviews current evidence on DMT and 5-MeO-DMT for mental disorders, highlighting therapeutic potential through 5-HT2A and 5-HT1A receptor agonism and neuroplasticity, but notes limited clinical trials.
review
Reviews chemical syntheses of bufotenin and 5-MeO-DMT, noting increased preclinical and clinical research interest but not providing clinical efficacy data.
review
Summarizes preclinical and clinical evidence on ayahuasca/DMT for multiple mental disorders, showing enhanced neuroplasticity and reduced DMN activity, but evidence is mainly observational and requires randomized trials.
review
Describes 5-MeO-DMT as a promising ultra-short-acting psychedelic for treatment-resistant depression, warranting larger RCTs.
review
EEG data showed selective gamma-band power enhancement near 43 Hz during peak conscious states (DMT/5-MeO-DMT breakthrough) compared to baselines, with non-random dynamics.
observational Sample size: 35
Psychedelics enhanced emotional empathy but had mixed effects on memory, reaction time, attention, and cognitive flexibility; many studies had small samples and placebo blinding challenges.
systematic review
Characterized metabolism of N1-sulfonated DMT derivatives, identifying phase I/II biotransformations and downregulation of L-threonine, but no clinical outcomes.
preclinical
Proposes the Axis Mundi hypothesis that endogenous DMT serves dual functions: neuroprotection via sigma-1 receptor agonism and modulation of conscious-subconscious boundary via 5-HT2A receptors.
theoretical
Endogenous DMT was undetectable in rat brain despite MAO inhibition, and exogenous DMT was not retained in serotonin terminals, challenging the hypothesis of DMT as a co-transmitter with serotonin.
preclinical
Same findings as article_id 24832: endogenous DMT below detection limits, and no evidence of DMT formation or retention in serotonin terminals.
preclinical
Describes a vaporizable formulation of 5-MeO-DMT and THCV as a potential treatment for TRD and anxiety, aiming to reduce panic responses while preserving neuroplastic benefits.
theoretical/patent
Points of agreement
- Multiple reviews agree that DMT and 5-MeO-DMT show therapeutic potential for treatment-resistant depression and other mental disorders.
- Studies consistently point to mechanisms involving 5-HT2A receptor agonism, neuroplasticity, and modulation of the default mode network.
- There is consensus that larger, placebo-controlled randomized trials are needed to confirm efficacy and safety.
Conflicts
- Preclinical studies (article_ids: 24832, 24829) found no evidence for endogenous DMT in rat brain, conflicting with the theoretical framework (article_id: 24868) that posits endogenous DMT as a functional neurotransmitter.
- The open-label trial (article_id: 24992) reports positive results, but systematic review (article_id: 24835) highlights mixed effects on cognitive functions and methodological limitations across psychedelic studies.
Gaps
- No large, double-blind, placebo-controlled randomized trials of DMT or 5-MeO-DMT for any indication were reported in February 2026.
- Durability of therapeutic effects beyond 12 weeks is not established.
- Optimal dosing, route of administration, and safety in special populations (e.g., bipolar, psychotic disorders) remain unstudied.
- The existence and function of endogenous DMT in the human brain is unresolved, with conflicting preclinical evidence.